Hims & Hers Health, Inc. (NYSE:HIMS) Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 10.5% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 200,000 shares of the company’s stock after buying an additional 19,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned 0.09% of Hims & Hers Health worth $3,094,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in Hims & Hers Health in the first quarter valued at $1,925,000. Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after acquiring an additional 136,907 shares during the last quarter. M&G Plc purchased a new position in shares of Hims & Hers Health during the 1st quarter worth about $8,232,000. Entropy Technologies LP purchased a new position in shares of Hims & Hers Health during the 1st quarter worth about $1,386,000. Finally, ProShare Advisors LLC boosted its position in shares of Hims & Hers Health by 10.0% in the first quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock worth $344,000 after acquiring an additional 2,023 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,335 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $20.28, for a total value of $47,353.80. Following the transaction, the insider now owns 169,144 shares of the company’s stock, valued at $3,430,240.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $12.54, for a total transaction of $2,368,655.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 2,335 shares of the stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $20.28, for a total transaction of $47,353.80. Following the completion of the sale, the insider now directly owns 169,144 shares in the company, valued at approximately $3,430,240.32. The disclosure for this sale can be found here. Insiders sold a total of 983,988 shares of company stock valued at $18,635,842 in the last quarter. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Up 3.3 %

Shares of HIMS opened at $23.26 on Friday. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74. The stock has a 50 day moving average of $20.92 and a 200-day moving average of $15.15.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The firm’s revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.05) earnings per share. Analysts expect that Hims & Hers Health, Inc. will post 0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Bank of America lifted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. TD Cowen upped their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Piper Sandler raised their target price on Hims & Hers Health from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, July 11th. Finally, Citigroup cut Hims & Hers Health from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $16.00 to $20.00 in a research note on Wednesday, May 22nd. Seven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.07.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.